immatics biotechnologies GmbH (4A3) — Capital Reinvestment Ratio
immatics biotechnologies GmbH (4A3) has a Capital Reinvestment Ratio of 0.12x as of December 2023, meaning it reinvests 0% of its operating cash flow (€79.08 Million) in capital expenditures (€9.29 Million). Check 4A3 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
immatics biotechnologies GmbH Capital Reinvestment Ratio (2018–2023)
This chart tracks immatics biotechnologies GmbH's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see immatics biotechnologies GmbH (4A3) cash conversion ratio.
Annual Capital Reinvestment Ratio for immatics biotechnologies GmbH (2018–2023)
Year-by-year Capital Reinvestment Ratio for immatics biotechnologies GmbH from 2018 to 2023. See immatics biotechnologies GmbH free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.70x | €18.23 Million | €30.96 Million | ▲ +2863.7% |
| 2022 | 0.06x | €100.13 Million | €5.74 Million | ▲ +12.4% |
| 2021 | 0.05x | €100.13 Million | €5.11 Million | ▼ -31.2% |
| 2020 | 0.07x | €100.13 Million | €7.42 Million | ▲ +145.4% |
| 2019 | 0.03x | €70.97 Million | €2.14 Million | ▲ +45.6% |
| 2018 | 0.02x | €20.68 Million | €429.00K | — |